AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

Shots:

  • The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months
  • The study resulted in a median time of 2.2 hours in achieving normal potassium levels in the blood, 98% achieved normal levels in 48 hours, rapid reduction of potassium in blood as early as one hour with one dose and a sustained treatment effect for up to one year, well-tolerated data
  • Lokelma is an insoluble oral powder formulation that results as a highly selective potassium-removing medicine approved in the US, EU, Canada to treat hyperkalemia and is under review in Japan with expected results in H1’20

Click here to read full press release/ article | Ref: AstraZeneca | Image: Behance